Search
Jazz Pharmaceuticals PLC
JAZZAdd to Watchlist
252.860USD
-5.520-2.14%
Close 07-31 16:00（ET）Quotes delayed by 15 min
15.88BMarket Cap
613.23P/E TTM
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Xywav
1.66B
38.83%
Epidiolex/epidyolex
1.06B
24.82%
Rylaze
402.92M
9.44%
Zepzelca
307.31M
7.20%
High-sodium oxybate AG royalty revenue
211.72M
4.96%
Other
629.45M
14.75%
By RegionUSD
Name
Revenue
Proportion
United States
3.83B
89.78%
Europe
341.12M
7.99%
All Others
94.87M
2.22%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Xywav
1.66B
38.83%
Epidiolex/epidyolex
1.06B
24.82%
Rylaze
402.92M
9.44%
Zepzelca
307.31M
7.20%
High-sodium oxybate AG royalty revenue
211.72M
4.96%
Other
629.45M
14.75%